Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
Rima M DaferGretchen E TietjenJohn F RothrockRobert E VannStephen B ShrewsburySheena K AuroraPublished in: Headache (2024)
In two separate studies, INP104 demonstrated a favorable CV safety profile when used in a study population without CV-related contraindications.